Background and Aims. The gut microbiome, an aggregate genome of trillions of microorganisms residing in the human gastrointestinal tract, is now known to play a critical role in human health and predisposition to disease. It is also involved in the biotransformation of xenobiotics and several recent studies have shown that the gut microbiota can affect the pharmacokinetics of orally taken drugs with implications for their oral bioavailability.


Results and Conclusions. Recent studies make it clear that the human gut microbiota can play a major role in the metabolism of xenobiotics and, the stability and oral bioavailability of drugs. Over the past 50 years, more than 30 drugs have been identified as a substrate for intestinal bacteria. Questions concerning the impact of the gut microbiota on drug metabolism, remain unanswered or only partially answered, namely (i) what are the molecular mechanisms and which bacterial species are involved? (ii) What is the impact of host genotype and environmental factors on the composition and function of the gut microbiota, (iii) To what extent is the composition of the intestinal microbiome stable, transmissible, and resilient to perturbation? (iv) Has past exposure to a given drug any impact on future microbial response, and, if so, for how long? Answering such questions should be an integral part of pharmaceutical research and personalised health care.

Key words: microbiome, metabolism of drugs, gut microbiota, bioavailability, cytochromes P450

INTRODUCTION

The human body carries trillions of microorganisms, whose aggregate genomes have substantial metabolic potential and are referred to as the microbiome. The largest number of these microorganisms resides in the gut and is termed the gut microbiota. Recent studies have shown that the commensal intestinal flora have profound effects on overall health of the host for which it performs various essential biological functions such as synthesis of vitamins, development and modulation of the immune system, bacterial defense, the intestinal response to epithelial cell injury and nutrient metabolism. Changes in the structure and diversity of the microbiome are also associated with large array of pathological states such as inflammatory bowel diseases (IBDs) (ref. 1), metabolic diseases such obesity and diabetes, atherosclerosis and cardiovascular disease. The gut microbiome is relatively stable but its composition and/or function may be influenced by a range of factors such as diet, probiotics, and drugs, especially antibiotics. Gut microbiota also affect the metabolism and toxicity of xenobiotics. They express a diverse array of bacterial enzymes which have the ability to metabolize drugs far more extensively than any other part of the body. Orally taken drugs reach the gastrointestinal tract and before being absorbed through the epithelial membrane into the blood they are exposed to the intestinal microbiota that may alter their disposition, efficacy and toxicity. Thus, the effect of intestinal microflora can have significant implication for the oral bioavailability and half-life of drugs. However, understanding of the effect of the intestinal bacteria on the stability of the drugs in the gastrointestinal environment remains limited.

COMPOSITION OF THE GUT MICROBIOTA

Our understanding of the composition and functions of the human gut microbiota is crucial to assess their metabolic potential and influence on human health. Over the last two decades, knowledge of this area has increased enormously, mainly due to the next-generation sequencing technologies and metabolite profiling. The majority of microbes in our bodies reside in the gastrointestinal tract and provides a wide range of interactions with the host. In addition to bacteria, the gut microbiota consists of archaea, yeasts and filamentous fungi. Recent studies have suggested that the viral component, including a variety of bacteriophages, is also important. Gut microbiota are an extremely diverse bacterial community (approximately 500 species per individual), however, the gastrointestinal tract of a healthy adult is typically represented by two dominant bacterial phyla, the gram-positive Firmicutes and gram-negative Bacteroidetes along with lower abundances...
of *Actinobacteria*, *Proteobacteria* and *Verrucomicrobia*). Bacteroides is the most abundant and the most variable genus. The human gastrointestinal tract is sterile in the prenatal period. During and immediately after birth, initial microbial exposure occurs. While, vaginally delivered infants are colonized by maternal vaginal and faecal microbiota, dominated by Lactobacillus, *Prevotella*, or *Sneathia* spp, infants born via caesarean delivery are instead, colonized with microbes associated with the skin, dominated by *Staphylococcus*, *Corynebacterium*, and *Propionibacterium* spp. and with the hospital environment. The genus *Bifidobacterium*, belonging to the phylum *Actinobacteria*, is a dominant microbial group in healthy breastfed babies. The role of this genus in gut homeostasis is summarized in a published review. Despite great individual variability, the gut microbiome of adults is considered to be relatively stable. According to Arumugan et al., 2011 the human population can be divided into only three enterotypes, identifiable by variation in the levels of one of three genera: *Bacteroides* (enterotype 1), *Prevotella* (enterotype 2) and *Ruminococcus* (enterotype 3) (ref. 24). Also during senescence, the composition of the gut microbiota undergoes new changes. Claesson et al. has found that elderly people differ from the core microbiota and diversity levels of younger adults, with a greater proportion of *Bacteroides* spp. and distinct abundance patterns of *Clostridium* groups.

Nevertheless, describing “the normal” gastrointestinal microbiota residing within healthy humans is still very challenging since most are anaerobic and uncultivable and also because of enormous individual differences.

**FACTORS INFLUENCING THE COMPOSITION AND FUNCTION OF THE MICROBIOME**

The human gut microbiota is one of the most complex ecosystems on the planet and many studies are focused on the investigation of the composition and function of the gut microbiota and their interaction with the host. Imbalance in the composition of this bacterial community can lead to transient intestinal dysfunctions and pathological states. In recent years, an increasing number of studies on the impact of several classes of drugs, xenobiotics and also dietary plant substances on the composition of the gut microbiota have been published. The microbial intestinal metabolism is adversely affected especially by antibiotics. According to recent studies, antibiotics produce drastic short- and long-term alteration and disruption of the gut microbiota which may lead to the partial decrease in the overall diversity of the microbiome. On the other hand, different studies indicated the plasticity of the gut microbial composition which can be reshaped after discontinuation of antibiotics.

However, the relationship between the composition of the gut microbiome and host organism is mutual and many recent studies have focused on this unique interaction. To date, a myriad of papers have reported the association of the activity of gut microbiome with obesity and diabetes mellitus, asthma and allergy, aging and even the development and function of the central nervous system, autism and depression.

**METABOLISM OF XENOBIOTICS**

With 100 trillion microbes encoding 100-fold more unique genes than our own genome and secreting a diverse array of bacterial enzymes, the gastrointestinal tract has enormous genetic and metabolic potential. The ability of the gut microbiome to metabolize drugs was first recognized over 40 years back. To date, dozens of drugs and diet-derived bioactive compounds have been reported to undergo direct microbial modification, and their number is still growing. In almost all cases, the exact mechanism, the specific reaction and the responsible microbial species remain unknown. However, several mechanisms have been proposed and demonstrated. Currently, new sequencing and pyrotequencing technologies allow new insights for answering the questions how gut microbiome affect the disposition, efficacy and toxicity of drugs. Several recent studies have shown that the gut microbiota can influence the pharmacokinetics of orally administered drugs and, thus, may have significant implications for their oral bioavailability.

**DRUGS METABOLIZED BY THE GUT MICROBIOTA**

**Azo reduction**

The first reported example of the azoreduction of drugs by gut microbiota was modification of orally administered prontosil and neoprontosil to sulfanilamide. Concurrently, this conversion was the first known prodrug activation by gut bacteria, as metabolite sulfanilamide was found to have antibacterial effect. Azoreductases produced by the large intestinal microbiota are responsible for the reduction of the azo bond. Prontosil is metabolized to sulfanilamide also in the liver and kidney (Fig. 1.). Ginger et al. (1971) has found that antibiotics are able to suppress the conversion of orally administered prontosil to sulfanilamide in the rat. Hence, concomitant intake of prontosil and antibiotics could affect the pharmacokinetics of prontosil and thus its bioavailability. Also, intraperitoneally injected prontosil undergoes gut bacterial metabolism since it can be transported into the gastrointestinal tract by the enterohepatic circulation. Neoprontosil, a high polar antibacterial drug, is also reduced by gut bacterial enzymes to the pharmacologically active metabolite sulfanilamide. However as a high polar drug, neoprontosil is not easily absorbed in the intestine and a large portion is excreted by bile, unchanged.

**Sulfasalazine** used in the treatment of inflammatory bowel disease belongs also into same group of sulfonamide drugs. In the colon, the azo bond of sulfasalazine is reduced by bacterial azoreductases forming two metabolites – 5-aminosalicylic acid (mesalazine) and sulfapyridine. On the other hand, unchanged sulfasalazine was found in the caecum and faeces of antibiotic-treated...
or with germ-free rats. A metabolite of sulfasalazine, sulfapyridine, is absorbed in the colon and could be reason of side effects of sulfasalazine in some patients, such as nausea, skin rash, headache, dizziness and loss of appetite. The synthesis of balsalazide from 4-aminobenzoyl-b-alanine and salicylic acid was an effort to obviate the side effects of sulfasalazine. Gut microbiota has been shown to metabolize balsalazide to 5-aminosalicylic acid. Another sulfasalazine analog, olsalazine, is converted into two 5-aminosalicylic acid molecules by azoreductase-containing bacteria.

**Nitro reductase**

Nitro reductases are the next commonly produced gut bacterial enzymes involved in the metabolism of drugs. Orally administered drugs with a nitro group are reduced to amino products via nitroso and hydroxylamino intermediates. A hypnotic, sedative and anticonvulsant drug of the benzodiazepine class, nitrazepam, undergoes nitro reduction catalyzed by the gut bacterial enzymes (Fig. 2) (ref.63). In this case, the bacterial metabolic activation does not produce pharmacologically active metabolite but products with teratogenic effects. The gastrointestinal tract is the primary site for nitro reduction of nitrazepam to 7-aminonitrazepam, followed by acetylation in the liver to 7-acetylaminonitrazepam, which is teratogenic in rats and mice. This reductive metabolism of nitrazepam occurs with less intensity in rat liver too. Nitro reduction is also involved in the bacterial modification of the next hypnotic, sedative anticonvulsant drug, clonazepam. The participation of the gut microbiota in this metabolism has been demonstrated by studies on germ-free and ex-germ-free rats.

**Misonidazole**

Misonidazole is a 2-nitroimidazole derivative, which is an effective radiosensitizer used in radiation therapy to cause normally resistant hypoxic tumor cells to become sensitive to the treatment. The metabolite of nitro reduction, 1-(2-aminomidazol-1-yl)-3-methoxypropan-2-ol, was found in the excreta of conventional rats in comparison with germ-free rats where the metabolite was not detected. One in vitro study showed that misonidazole is metabolized by gut microbiota into its amino derivative.

**Sulfoxide reduction**

Sulfinpyrazone is a uricosuric medication used to treat thromboembolic disorders. In the light of experiments on healthy volunteers and ileostomy patients receiving a single oral dose of sulfinpyrazone, the intestinal microbiota seems to be only site of sulfinpyrazone reduction in man. The same study also reported the participation of gut microbiota in the formation of sulfinpyrazone in rabbits in vitro and in vivo. Sulindac, also containing the sulfinyl functional group, is a non-steroidal anti-inflammatory drug and is used to treat acute and chronic inflammatory conditions. Strong et al. showed that sulindac is reduced by gut microbiota to sulindac sulide in man and also in vivo and in vitro in rabbits.

**Omeprazole**

Omeprazole is a derivative of benzimidazole used to treat gastroesophageal reflux disease, peptic ulcer and as a prevention of upper gastrointestinal bleeding. Omeprazole inhibits H+/K+-ATPase in the parietal cell, suppressing gastric acid secretion. The pharmacokinetics of omeprazole is influenced by gut bacteria, which reduce omeprazole to sulfide metabolites. This reductive metabolism has only been reported under in vitro conditions. Orally administered omeprazole is well absorbed and does not reach the distal gut. Thus bacterial enzymes are unlikely to be involved in this metabolism.

**N-oxide reduction**

Ranitidine and Nizatidine is a histamine H2 receptor antagonist that inhibits stomach acid production commonly used in the treatment of peptic ulcer and gastroesophageal reflux disease. Using a batch culture fermentation system simulating the colon condition, ranitidine was shown to undergo cleavage on an N-oxide bond causing decreased concentration of the drug.

**Fig. 1. Azo reduction of prontosil is one example, where intestinal bacteria convert inactive therapeutics into their pharmacologically active form. Bacterial azoreductases present in the distal gut cleave the N-N double bond and produce active metabolite sulfanilamide.**

**Fig. 2. Nitro reduction of nitrazepam catalyzed by the gut bacterial enzymes produce teratogenic metabolite, 7-Aminonitrazepam. It is an example of clinically undesirable side effect caused by the gut microbiota.**
metabolic modification seems to be partly responsible for the impaired absorption of ranitidine from the colon. In a subsequent study, nizatidine was found to be metabolized via cleavage on an N-oxide bond in the presence of colonic bacteria to hydroxyiminonizatidine, while cimetidine and famotidine did not undergo such bacterial metabolism. Antibiotics such as rifampicin were found to decrease the absorption of ranitidine in the gastrointestinal tract.

Other reductions

Digoxin is a cardiac glycoside used in the treatment of atrial fibrillation, atrial flutter and sometimes heart failure that cannot be controlled by other medication. A primary mechanism of action of digoxin is inhibition of the Na⁺/K⁺ ATPase, mainly in the myocardium. The absorption and bioavailability of oral digoxin was a topic of much research 40 years ago. In the human body, digoxin may be converted to the inactive metabolites – dihydrodigoxin and dihydroidigoxigenin. These reduced derivatives bind poorly to the Na⁺/K⁺ ATPase of cardiac cells and have lower cardiac activity. It has been shown that colonic bacteria are mainly responsible for the formation of these two pharmacologically inactive metabolites.

When the digoxin was given intravenously, the smaller amount of reductive metabolites was found. Lindenbaum et al. (1981) also suggest that the presence of reduced metabolites depends on the individual composition of the intestinal microbiome, since only 10% of patients on prolonged digoxin treatment excluded reduced derivatives of digoxin. The administration of erythromycin and tetracycline suppresses the reduction of digoxin in vitro and in vivo. Reduction of digoxin to dihydrodigoxin and dihydroidigoxigenin is an example of the pharmacological inactivation of drug by gut microbiota in man.

Zonisamide is a sulfonamide anticonvulsant used to treat epilepsy. By reduction of the benzisoxazole ring, zonisamide is primarily converted to 2-sulfamoylacetylphenol in vitro. One in vivo experiment on rats showed, that the intestinal microbiota are mainly involved in this modification of zonisamide. Experiments on caecal fluids from rats, mice, hamsters, rabbits, and guinea-pigs also reported the reductive metabolism forming 2-sulfamoylacetylphenol. In line with these results, one experiment with concomitantly administered antibiotics and zonisamide in rats, showed that the antibiotics significantly inhibited the urinary and faecal excretion of 2-sulfamoylacetylphenol, while re-contamination of the
Nabumetone, (4-(6-methoxy-2-naphthyl)-2-butanone), is a widely used as a non-acidic, non-steroidal anti-inflammatory prodrug. After oral administration, nabumetone is converted by oxidative cleavage of its side chain to active metabolite 6-methoxy-2-naphthylacetic acid (6-MNA), a very strong COX-2 inhibitor. Nabumetone is used mainly for the management of pain and inflammation in patients with osteoarthritis and rheumatoid arthritis. The metabolism of nabumetone is well known. Recently, new metabolites of I. phase biotransformation were identified (Fig. 3) (ref.78). When nabumetone was incubated with live bacterial suspension of commensal E. coli ATCC 25922, a reduced pharmacologically inactive metabolite reduced nabumetone was detected (Fig. 4) (unpublished data). These data suggest that gut bacteria are involved in the metabolism of nabumetone and may cause lower absorption of nabumetone and thus, lower bioavailability of the drug. On the basis of these data, a broad spectrum antibiotic, imipenem, was given to rats to evaluate possible effects of antibiotic on the pharmacokinetics of nabumetone. The pharmacokinetics of the main metabolite of nabumetone in the rat plasma, however, was not significantly influenced.

Metronidazole, a 5-nitroimidazole derivative, is used as an antibiotic and antiprotozoal drug. In the liver, metronidazole is metabolized by side-chain oxidation or glucuronidation to form more polar metabolites. Metronidazole can also undergo reductive modification, when enzymes of anaerobic bacteria disrupt the imidazole ring and produce reduced metabolites - N-(2-hydroxyethyl)-oxamic acid and acetamide. Involvement of the gut bacteria in reductive metabolism of metronidazole has been demonstrated in experiments with germ-free rats, since the metabolites N-(2-hydroxyethyl)-oxamic acid and acetamide were only found in excreta of conventional rats and not in the urine or faeces of germ-free rats. One in vitro study with C. perfringens or rat caecal contents also confirmed the formation of these metabolites. N-(2-hydroxyethyl)-oxamic acid and acetamide were detected in small amounts in the urine of patients treated with metronidazole. According to four randomized clinical trials, coadministration of mexitazalamine was found to have no effect on the pharmacokinetics of metronidazole.

Hydrolysis

The metabolism of sorivudine is a good example of the importance of studying the metabolites of orally administered drug and possible changes in their pharmacological activity or even toxicity. The stability of drugs in the intestinal lumen and potential involvement of the gut bacteria on the metabolism should not be overlooked. Sorivudine is a thymine analogue used as an antiviral drug released onto the Japanese market in 1993. The antiviral effect of sorivudine is due to competitive inhibition of viral DNA polymerase. However, eighteen acute deaths of patients were caused by coadministration of sorivudine with oral antibiotic-treated rats with microbiota restored the excretion.

Fig. 4. Chromatographic separation of nabumetone and its metabolites after incubation with the commensal bacteria E. coli ATCC 25922.
l-DOPA and forming the metabolites.

Crobiota in the dehydroxylation of the catechol ring of faecal content confirmed the importance of the gut microbiota in the dehydroxylation of the catechol ring of faecal content. This metabolite was detected when rat caecal content was incubated with phenacetin under anaerobic conditions. The formation of p-phenetidine is relevant to some clinical complications of phenacetin use, such as methemoglobinemia and nephritis.

Acetylation

5-aminosalicylic acid (5-ASA, mesalazine), active metabolite of the prodrugs sulphasalazine, balsalazide and olsalazine, is an anti-inflammatory drug used to treat inflammatory bowel disease, such as ulcerative colitis. Small part of orally administered 5-ASA (or its prodrugs) is acetylated by the gut microbiota to N-acetyl-5-aminosalicylic acid. In vitro studies have shown that the intestinal bacteria of rats, guinea pigs, dogs and humans are capable of acetylating both 5-ASA and also sulfapyridine. Experiments with faecal suspension of germ-free rats, have shown no acetylating activity. In human faecal suspension, 5-ASA undergoes acetylation under both aerobic and anaerobic conditions as well as by individual bacteria.

Fig. 5. Bacteroides sp. are responsible for lethal toxicity of sorivudine when concomitantly administered with 5-fluorouracil. Sorivudine metabolite of bacterial metabolism, (E)-5-(2-bromovinyl) uracil causes toxic level of anticancer drug 5-fluorouracil.

5-fluorouracil prodrugs, an anticancer drug. Okuda et al. (1998) investigated the exact mechanism of this toxicity and found that sorivudine metabolite produced by bacterial fermentation was responsible for the lethal effect (Fig. 5). The metabolite (E)-5-(2-bromovinyl) uracil, produced from sorivudine by gut microbiota – mainly Bacteroidetes species, can inhibit the metabolism of 5-fluorouracil and cause toxic levels of the drug. Furtherstudies with germ-free rats indicated that for the formation of (E)-5-(2-bromovinyl) uracil, enterobacteria are mainly responsible. Shortly after the deaths of patients, sorivudine was withdrawn from the market.

Lactulose, the keto analogue of lactose (4-((β-D-galactopyranosyl)-D-fructose), is a non-absorbable sugar used to treat constipation and hepatic encephalopathy. The enzymes of the intestinal bacteria (Lactobacillus, Bacteroides, E. coli) catalyze the hydrolysis of lactulose into fructose and galactose followed by conversion to lactic and acetic acids, which lower the pH within the intestine. Lower pH is favorable for protonization of ammonia and other amines, which can then be eliminated in faeces. This is the mechanism of the laxative effect of lactulose.

Dehydroxylation

L-DOPA. L-3,4-dihydroxyphenylalanine, is used in the clinical treatment of Parkinson's disease caused by dopamine depletion in the substantia nigra. Orally administered L-dopa undergoes decarboxylation in the central nervous system and increases the level of dopamine. However, the principal site for l-Dopa decarboxylation seems to be the gastrointestinal tract. The products of decarboxylation are m-tyramine and m-hydroxyphenylacetic acid, which were detected in the urine of conventional rats but not in pathogen free animals. One study on rat faecal content confirmed the importance of the gut microbiota in the dehydroxylation of the catechol ring of L-dopa and forming the metabolites.

Deacetylation

Phenacetin was one of the first synthetic antipyretic drugs on the market introduced in 1887 and mainly used as an analgesic. Orally administered phenacetin is rapidly absorbed from the small intestine and metabolized in the liver to paracetamol (acetaminophen). Only a small amount of phenacetin is deacetylated to p-phenetidine. This metabolite was detected when rat caecal content was incubated with phenacetin under anaerobic conditions. The formation of p-phenetidine is relevant to some clinical complications of phenacetin use, such as methemoglobinemia and nephritis.

Acetylation

5-aminosalicylic acid (5-ASA, mesalazine), active metabolite of the prodrugs sulphasalazine, balsalazide and olsalazine, is an anti-inflammatory drug used to treat inflammatory bowel disease, such as ulcerative colitis. Small part of orally administered 5-ASA (or its prodrugs) is acetylated by the gut microbiota to N-acetyl-5-aminosalicylic acid. In vitro studies have shown that the intestinal bacteria of rats, guinea pigs, dogs and humans are capable of acetylating both 5-ASA and also sulfapyridine. Experiments with faecal suspension of germ-free rats, have shown no acetylating activity. In human faecal suspension, 5-ASA undergoes acetylation under both aerobic and anaerobic conditions as well as by individual bacteria.

Thiazole ring opening

Levamisole, a synthetic imidazothiazole derivative was originally used to treat worm infestations in both humans and animals and the combination with other drugs is used to treat some tumour diseases. Human gut bacteria, mainly Bacteroidetes and Clostridium spp. metabolize levamisole into three metabolites with opened thiazole ring under anaerobic conditions, levametabol-I, levametabol-II, and levametabol-III. Co-administered with antibiotics, levamisole has a stronger clinical effect due to inhibition of its bacterial metabolism by intestinal bacteria.

Isoxazole scission

Risperidone is an antipsychotic medication exhibiting a very potent serotonin receptor – 5-HT antagonism used to treat schizophrenia, bipolar disorder, and irritability in people with autism. Orally administered risperidone is effectively absorbed and its oral bioavailability is approximately 70% (ref.95). Gut microbiota of rats converts risperidone into dihydroxy-risperidone and hydroxyl-keeto-risperidone under both aerobic and anaerobic conditions. In the liver, antibiotics decrease the bioavailability of risperidone. No gut bioavailability has been reported.

Deamination

Flucytosine, a fluorinated pyrimidine analogue, is a synthetic antimycotic drug. Verme et al. found that bacterial enzymes metabolize flucytosine to 5-fluorouracil, since bacterial metabolism was less pronounced in patients treated with antimicrobial agents.

Other reactions

Lovastatin is a statin drug and potent competitive inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (a rate limiting enzyme in cholesterol synthesis), used to lower cholesterol levels to reduce risk of cardiovascular disease. Lovastatin is metabolized by human liver to more polar hydroxyl metabolites. It has long been known that lovastatin and related compounds
Table 1. Summary of drugs metabolized by gut microbiota.

<table>
<thead>
<tr>
<th>Clinical use</th>
<th>Drug</th>
<th>Influence on drugs</th>
<th>Type of microbial metabolism</th>
<th>Bacterial species involved</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibiotics</td>
<td>Prontosil</td>
<td>prodrug activation</td>
<td>Azo reduction</td>
<td>unknown</td>
<td>55, 56</td>
</tr>
<tr>
<td></td>
<td>Neoprontosil</td>
<td>prodrug activation</td>
<td>Azo reduction</td>
<td>unknown</td>
<td>55, 56</td>
</tr>
<tr>
<td></td>
<td>Metronidazole</td>
<td>increase toxicity</td>
<td>Reduction</td>
<td>unknown</td>
<td>81, 82</td>
</tr>
<tr>
<td></td>
<td>Chloramphenicol</td>
<td>increase toxicity</td>
<td>Amine formation and hydrolysis</td>
<td>unknown</td>
<td>103</td>
</tr>
<tr>
<td></td>
<td>Sulfasalazine</td>
<td>prodrug activation</td>
<td>Azo reduction</td>
<td>unknown</td>
<td>57-59</td>
</tr>
<tr>
<td></td>
<td>Balsalazine</td>
<td>prodrug activation</td>
<td>Azo reduction</td>
<td>unknown</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>Olsalazine</td>
<td>prodrug activation</td>
<td>Azo reduction</td>
<td>unknown</td>
<td>61</td>
</tr>
<tr>
<td></td>
<td>Sulfinpyrazone</td>
<td>increased activity</td>
<td>Sulfoxide reduction</td>
<td>unknown</td>
<td>68</td>
</tr>
<tr>
<td></td>
<td>Sulindace</td>
<td>increased activity</td>
<td>Sulfoxide reduction</td>
<td>unknown</td>
<td>68</td>
</tr>
<tr>
<td></td>
<td>Nabumetone</td>
<td>probably lower bioavailability</td>
<td>Reduction</td>
<td>unknown</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>Mezalazine</td>
<td></td>
<td>Acetylation</td>
<td>unknown</td>
<td>91-93</td>
</tr>
<tr>
<td>Anti-inflammatory</td>
<td>Sulfasalazine</td>
<td>prodrug activation</td>
<td>Azo reduction</td>
<td>unknown</td>
<td>57-59</td>
</tr>
<tr>
<td></td>
<td>Balsalazine</td>
<td>prodrug activation</td>
<td>Azo reduction</td>
<td>unknown</td>
<td>60</td>
</tr>
<tr>
<td>drugs</td>
<td>Olsalazine</td>
<td>prodrug activation</td>
<td>Azo reduction</td>
<td>unknown</td>
<td>61</td>
</tr>
<tr>
<td></td>
<td>Sulfinpyrazone</td>
<td>increased activity</td>
<td>Sulfoxide reduction</td>
<td>unknown</td>
<td>68</td>
</tr>
<tr>
<td></td>
<td>Sulindace</td>
<td>increased activity</td>
<td>Sulfoxide reduction</td>
<td>unknown</td>
<td>68</td>
</tr>
<tr>
<td></td>
<td>Nabumetone</td>
<td>probably lower bioavailability</td>
<td>Reduction</td>
<td>unknown</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>Mesalazine</td>
<td></td>
<td>Acetylation</td>
<td>unknown</td>
<td>91-93</td>
</tr>
<tr>
<td>Analgesics</td>
<td>Acetaminophen</td>
<td>increased toxicity</td>
<td>O-sulfation; C-S cleavage of acetaminophen-3-cysteine</td>
<td>unknown</td>
<td>106</td>
</tr>
<tr>
<td></td>
<td>Phenacetin</td>
<td>decreased activity</td>
<td>Deacetylation</td>
<td>Deacetylation</td>
<td>90</td>
</tr>
<tr>
<td>Cardiotonics</td>
<td>Digoxin</td>
<td>decreased cardiac activity</td>
<td>Reduction</td>
<td>Eggerthella lenta</td>
<td>75, 76</td>
</tr>
<tr>
<td></td>
<td>L-Dopa</td>
<td>decreased activity</td>
<td>Dehydroxylation</td>
<td>unknown</td>
<td>89</td>
</tr>
<tr>
<td></td>
<td>Zonisamide</td>
<td>affect reduction</td>
<td>Reduction</td>
<td>unknown</td>
<td>77</td>
</tr>
<tr>
<td>Anti-psychotics</td>
<td>Risperidone</td>
<td>inducting symptoms of</td>
<td>Isoxazole scission or hydroxylation</td>
<td>unknown</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>L-Dopa</td>
<td>decreased activity</td>
<td>Dehydroxylation</td>
<td>unknown</td>
<td>89</td>
</tr>
<tr>
<td></td>
<td>Zonisamide</td>
<td>affect reduction</td>
<td>Reduction</td>
<td>unknown</td>
<td>77</td>
</tr>
<tr>
<td>Antiviriotics</td>
<td>Sorivudine</td>
<td>its microbial metabolite</td>
<td>Hydrolysis</td>
<td>Bacteroides</td>
<td>87, 85</td>
</tr>
<tr>
<td></td>
<td>Clavulinate</td>
<td>increased activity or toxicity</td>
<td>Deamination</td>
<td>unknown</td>
<td>98</td>
</tr>
<tr>
<td></td>
<td>Lovastatine</td>
<td>altered pharmacokinetics</td>
<td>Hydrolysis</td>
<td>unknown</td>
<td>52, 100-102</td>
</tr>
<tr>
<td>Antifungals</td>
<td>Clavulinate</td>
<td>increased activity or toxicity</td>
<td>Deamination</td>
<td>unknown</td>
<td>98</td>
</tr>
<tr>
<td></td>
<td>Lovastatine</td>
<td>altered pharmacokinetics</td>
<td>Hydrolysis</td>
<td>unknown</td>
<td>52, 100-102</td>
</tr>
<tr>
<td>Hypnotics</td>
<td>Nitrazepam</td>
<td>inducing teratogenicity</td>
<td>Nitro reduction</td>
<td>Clostridium leptum</td>
<td>63-65</td>
</tr>
<tr>
<td></td>
<td>Clonazepam</td>
<td>Nitro reduction</td>
<td>unknown</td>
<td>66</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Misonidazole</td>
<td>Nitro reduction</td>
<td>unknown</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Omeprazole</td>
<td>forming sulfide metabolites</td>
<td>Sulfoxide reduction</td>
<td>unknown</td>
<td>69</td>
</tr>
<tr>
<td>Antiulcerotics</td>
<td>Ranitidine</td>
<td>decreased intestinal absorption and systemic bioavailability</td>
<td>N-oxide reduction</td>
<td>unknown</td>
<td>70</td>
</tr>
<tr>
<td></td>
<td>Nizatidine</td>
<td>N-oxide reduction</td>
<td>unknown</td>
<td>72</td>
<td></td>
</tr>
<tr>
<td>Anthelmintics</td>
<td>Levafoxin</td>
<td>increased activity</td>
<td>Thiazole ring opening</td>
<td>Bacteroides and Clostridium spp.</td>
<td>94</td>
</tr>
<tr>
<td></td>
<td>Levamisole</td>
<td>increased activity</td>
<td>Thiazole ring opening</td>
<td>Bacteroides and Clostridium spp.</td>
<td>94</td>
</tr>
<tr>
<td>Prebiotics</td>
<td>Lactulose</td>
<td>stimulating the growth of beneficial bacteria</td>
<td>Hydrolysis</td>
<td>unknown</td>
<td>88</td>
</tr>
</tbody>
</table>

can be metabolized by the gut microbiota to a phosphorylated derivative and a number of hydroxylated microbial metabolites. Lovastatin is a lactone prodrug that is readily hydrolyzed in vivo to form the pharmacologically active 2-hydroxy lovastatic acid. The involvement of gut microbiota in the metabolism of lovastatin to its bioactive metabolite was demonstrated in vitro and in vivo in experiments with rats. Administration of antibiotics has been shown to reduce the bacterial metabolism ofLovastatin in the intestine and thus, decreases the bioavailability of the active metabolite, mainly due to antibiotic-mediated inhibition of intestinal bacteria. 

323
**Chloramphenicol** is an antibiotic with a broad spectrum activity used to treat a number of bacterial infections. Chloramphenicol contains an amide of dichloroacetic acid and a nitrobenzene group which undergoes bacterial metabolism in the gastrointestinal tract. Incubation of chloramphenicol with bacteria commonly found in human faeces has shown that the gut microbiota is able to metabolise chloramphenicol into a several metabolites, including the toxic metabolite p-aminophenyl-2-amin-1,3-propanediol related to risk of marrow aplasia\(^{103}\). Marrow aplasia has been shown only in a few percent of patients given chloramphenicol orally and microbiota contained a large amount of coliform microorganisms capable of producing toxic metabolites of chloramphenicol\(^{103}\).

**Acetaminophen** (N-acetyl-p-aminophenol, paracetamol) is one of the most widely used nonprescription medicines in the world for its analgesic and antipyretic properties. The biotransformation and potential toxicity of acetaminophen have been intensively studied and the fate of this drug in the human body is be well known\(^{104,105}\). Orally prescribed acetaminophen is mostly modified into two pharmacologically inactive metabolites, glucoronide and sulfate. A minor fraction is oxidized primarily by cytochromes P450 into a reactive metabolite NAPQI (5-10%), which is responsible for acetaminophen induced toxicity. NAPQI is detoxified by binding with glutathione to form acetaminophen glutathione conjugate, which is ultimately eliminated by the urine. The liver, and to a lesser extent the kidney are the major organs involved in the metabolism of acetaminophen but intestinal bacteria are also engaged, since two microbial metabolites p-cresol sulfate and phenylethylglutathione have been found. The microbial metabolite p-cresol undergoes o-sulfonation to produce the p-cresol sulfate and competes for the binding site of sulfotransferases with acetaminophen leading to increased acetaminophen toxicity\(^{106}\). In the light of these results, the role of the gut microbiota in the metabolism of drugs and the microbiome profile/composition of an individual should be taken into consideration, even with the conventionally used drugs with very well studied metabolism such as acetaminophen.

The list of all described drugs is summarized in Table 1.

**CONCLUSION**

On the basis of recent studies, the human gut microbiota can play a major role in the metabolism of xenobiotics and affect the stability and oral bioavailability of drugs. In the last 50 years, more than 30 drugs have been identified as a substrate for intestinal bacteria. Many questions concerning the impact of the gut microbiota on drug metabolism, however, remain unanswered or answered only partially, namely (i) what are the molecular mechanisms and which bacterial species are involved? what is the impact of host genotype and environmental factors on the composition and function of the gut microbiota, (iii) to what extent is the composition of the intestinal microbiome stable, transmissible, and resilient to perturba-

**REFERENCES**


